Leica Aperio iQC DX
Aperio iQC DX is Leica Biosystems' AI quality check for digital pathology slides. Clinical laboratories that scan slides on Leica's Aperio GT scanners use it to catch bad scans before a pathologist sees them.
After each slide is scanned, the software looks for six common problems, such as blur, air bubbles, pen marks and missing tissue. Flagged slides pop up on the scanner and in a dashboard, where a technician accepts them or sends them back to be rescanned or remade. Leica says it cut technician quality check time by up to 69 percent in a study at Heidelberg University.
The FDA cleared it in August 2026, and it carries the CE mark in Europe. It works only with Leica's own scanners and runs on a server in the laboratory. It does not diagnose anything.
Leica Biosystems is part of Danaher. No price is published.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
The AI is the product. Aperio iQC DX is software that does one job: a deep learning model checks each scanned slide for six common quality problems and flags the ones that need another look. The FDA's decision summary for the clearance (K253561) describes the model as convolutional neural networks, locked so they do not change in use. Without the model, the dashboard would have nothing to show.
The Aperio GT 450 DX and GT 180 DX scanners it works with are separate products and run without it.
Both what the software does and how far to trust it are published. It flags slides and does nothing else, and it never rejects or rescans a slide on its own. Leica says slides are processed within 31 seconds of scanning, so flags reach the scanner console while the slide is still in the scanner. A technician reviews every flagged slide in the dashboard and accepts or rejects it, with a comment for each rejection. Scan problems are fixed by rescanning. Preparation problems need the glass slide remade first.
Lab administrators set the detection thresholds for blur, striping, air bubbles and pen marks, and changes apply to new scans only. The user guide tells laboratories not to rely on the software alone and to keep their existing quality sampling, because it may miss some artifacts and flag others wrongly. A pathologist stays responsible for the diagnostic review, and serious incidents go to Leica and the regulator.
The model, its version and its training data are described. Update practice is not. The FDA's decision summary for K253561 says Aperio iQC DX version 1.0 uses deep learning convolutional neural networks, locked so they do not change in use. They were trained on 12,278 slides (5,158 H&E and 7,127 immunohistochemistry) scanned on the Aperio GT 450, tuned on 2,450 more and tested on 4,752 kept apart. The slides came from outside suppliers or an internal Leica site, with no count of sources.
How a new version reaches laboratories, and how they are told, is not published.
The chain is short. The model is Leica's own, locked and cleared under Leica's name (K253561), so it cannot be swapped for another supplier's model without going back to the FDA. It runs on the laboratory's own server, and the user guide says nothing is sent to Leica in normal operation. The parts it depends on are named: Ubuntu, NVIDIA graphics cards, and Leica's own scanners and SAM DX server.
No software bill of materials is published.
The main evidence is the test behind the FDA clearance (K253561, 7 August 2026). It used 4,752 whole slide images kept apart from the training data, with experts marking the true artifacts and a second reviewer and an arbiter checking them.
On the GT 450 DX scanner, the software caught between 93.2 and 99.7 percent of slides with each artifact type. It wrongly flagged between 0.1 and 7.3 percent of clean slides. Air bubbles had the lowest catch rate (883 affected slides). Missing or clipped tissue had the most false flags, with 92.7 percent of clean slides passed correctly (2,568 slides). Results on the GT 180 DX were comparable.
Leica's headline claims come from a real world study with the Institute of Pathology at Heidelberg University: up to 24 percent more artifacts caught that technicians had missed, and up to 69 percent less hands on review time. Neither the product page nor the announcement gives that study's method or slide counts.
Leica states where data goes and how long it stays. Images and results are kept on the laboratory's server for up to seven days, and event logs for six months. The user guide says nothing is sent to Leica in normal operation, and data is encrypted in transit and at rest. The model is locked and does not learn from the laboratory's slides. The FDA's decision summary says it was trained on de identified slides bought from outside suppliers or prepared at an internal Leica site.
What is missing is a written statement that customer data is never used for training, and what leaves the laboratory during service. Safety engineering, meaning guardrails and how a safety event is handled, is not published beyond reporting serious incidents to Leica and the regulator.
No business associate status is stated, though Leica's product documents take a clear position on where data goes. The user guide says images and results stay on the laboratory's own server for up to seven days, and that nothing is sent to Leica in normal operation. Slide label images carry patient identifiers, so that server holds protected health information.
Leica's privacy policy describes its scope as its websites, applications and other digital services and products. The policy's full text may say more on this. Leica representatives install the software, and the specifications call for an internet upload connection without saying what it carries.
Leica describes the product's security controls, and the FDA reviewed its cybersecurity documentation as part of the clearance. That review checks the software, not how Leica runs security, and no audit of Leica's own operations is published.
The user guide says users sign in with their Aperio SAM DX credentials, access depends on role, and data is encrypted in transit and at rest. Leica runs a coordinated vulnerability disclosure process and publishes product security advisories. No SOC 2 report, ISO 27001 certificate or penetration test is published on Leica's product security page or the product's own pages.
The US position is clear and checkable. The FDA cleared Aperio iQC DX Software, version 1.0, on 7 August 2026 under 510(k) K253561, as a Class II device (product code SIX, 21 CFR 864.3700). The predicate is Leica's Aperio GT 450 DX system.
The indication is an AI aid for finding artifacts in whole slide images of H&E and immunohistochemistry stained tissue that need a further image quality check before pathologists review them. It is not for diagnosis, prognosis or prediction of disease. Leica's marketing matches that use, and Leica calls it the industry's first FDA cleared AI quality control software.
Leica's user guide shows the CE mark under the European IVDR and the UKCA mark.
The FDA's decision summary for K253561 reports Leica's test results by stain and by scanner, and shows where the software is weaker. On the GT 450 DX, it caught 99.6 percent of air bubbles on H&E slides but 90.6 percent on immunohistochemistry slides. Results on the GT 180 DX were reported separately and were comparable. In a repeatability test, rotated copies of the same slides got the correct call every time, on both scanners and both stain families.
Results are not broken out by tissue type or immunohistochemistry marker. No process for governing model changes is described beyond the model being locked.
An error rate with its method and counts is published, and nothing stands behind it. The FDA's decision summary for K253561 (7 August 2026), a clearance Leica announces as its own, reports a test set result on 4,752 slides kept apart from training, checked against expert annotation with a second reviewer and an arbiter. It covers H&E and immunohistochemistry slides on the Aperio GT 450 DX and GT 180 DX.
On the GT 450 DX, the software caught 93.2 to 99.7 percent of slides with each artifact and passed 92.7 to 99.9 percent of clean slides correctly. For air bubbles, it caught 93.2 percent of 883 affected slides in a set of 2,134. These are test results, not performance in use.
Leica's user guide warns that the software may miss artifacts or flag clean slides, and the warranty sits in its standard terms and conditions. No guarantee, indemnity or remedy tied to a missed artifact is published.
Integration is limited to Leica's own systems. The software reads scanned images from a network share fed by Aperio GT 450 DX or GT 180 DX scanners. It signs users in through Leica's Aperio SAM DX server, and shows results on the scanner console and in its own dashboard. The specifications mention DICOM access without naming a system.
No connection to a laboratory information system or a third party image management system is published.
The software runs inside the laboratory. It installs on a physical or virtual server the laboratory provides, running Ubuntu 24.04, next to its Aperio scanners and SAM DX server. Images and results stay on that server for up to seven days, and the user guide says nothing is sent to Leica in normal operation.
One path is left open. The specifications call for a 100 Mbps internet upload link, while the user guide says the system works on the local network. What the connection carries is not stated.
No price is published, but how the product is sold can be worked out. Aperio iQC DX is software for laboratories that scan on Leica's Aperio GT 450 DX or GT 180 DX. It runs on a server the laboratory provides, physical or virtual, with one to four NVIDIA L4 graphics cards. Leica representatives install it and train staff.
The product page routes to a sales contact. No license term or unit of charge is stated.
The setting is narrow and stated precisely. The software checks image quality in clinical histology laboratories, before a pathologist reviews the slides. It covers H&E and immunohistochemistry stained, formalin fixed, paraffin embedded tissue scanned on the Aperio GT 450 DX or GT 180 DX. It looks for six problems: out of focus areas, image striping, missing tissue, clipped tissue, air bubbles and pen marks.
The test behind the FDA clearance (K253561) validated each problem type on both scanners and both stain families, with results reported separately. Leica's user guide lists known limits for each type, such as faint staining, and warns that results may be worse on unusual tissue, stains or other scanners. Tissue folds are not among the problems it is cleared to find.
Alternatives to Leica Aperio iQC DX
Other products that do the same kind of work as Leica Aperio iQC DX, and what each one does.
Mindpeak sells AI that scores cancer biomarkers on pathology slides, which laboratories use to quantify HER2, ER, PR, Ki-67 and PD-L1 on immunohistochemistry and H&E images.
Indica Labs sells HALO AP Dx, an enterprise digital pathology platform that clinical laboratories use for primary diagnosis on digital slides, along with its own clinical AI and the HALO research software used by pharma and research institutes.
Pramana makes whole slide imaging scanners that use real time AI during acquisition: quality control that detects artifacts such as bubbles, folds, debris and faint tissue and rescans automatically, tissue detection and region selection, and edge algorithms for feature detection while the…
Paige sells AI applications that help pathologists find and classify cancer on digitized slides, for prostate, breast, gastrointestinal and pan cancer pathology, along with a pathologist co-pilot called Alba, the FullFocus viewer and a family of foundation models (Virchow, Virchow2…
Proscia sells Concentriq, a digital pathology platform that clinical laboratories and life sciences organizations use to manage, view and analyze whole slide images.
Aiosyn sells AI that analyzes images of stained tissue, to pathology laboratories and to drug companies running animal studies.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Not published
|
Quote based. On premises software for Aperio GT 450 DX and GT 180 DX scanners, installed by Leica on a laboratory provided server with NVIDIA L4 graphics cards. No unit of charge published. | Not published. Images and results stay on the laboratory's server; Leica states nothing is sent to it in normal operation. | Not published. Installation and training are performed by Leica representatives. | Vendor Published |
No price is published for Aperio iQC DX, and the product page routes to a sales contact.
The software is sold to laboratories that scan on Leica's Aperio GT 450 DX or GT 180 DX. The laboratory supplies the server, physical or virtual, with one to four NVIDIA L4 graphics cards, and Leica installs the software and trains staff.
No unit of charge is stated, whether per scanner, per slide or per site, and the cost of the server hardware falls to the laboratory.